Comparison of my Axumin and PSMA PET scans had shown high overlap of PSMA and non-PSMA expressing cancer cells. This was a positive prognosis for the Lu PSMA treatment. When my PSA and ALP continued to rise during treatment, I had surmised that there wasn't close enough overlap on the cellular level for the overshoot of the beta particles to kill the non-PSMA expressing cells. Before and after Axumin scans tell a different story.
I got an Axumin scan on Tuesday and It showed dramatic reduction in the bony lesions in the prior PSMA expressing areas. It also showed considerable new growth in other bones. It appears that this new growth isn't expressing PSMA.
Members have expressed concern that Lu PSMA treatment can lead to repopulation with Neuroendocrine Prostate Cancer (NEPC), but I don't think that is what is happening. NEPC doesn't express PSA, and I had a rapid rise in PSA during treatment. I think the new growth is adenocarcinoma that isn't expressing PSMA.
I'm not sure what this means in terms of how the treatment could have been made more effective. There seems to be anecdotal evidence that combining enzalutamide with Lu PSMA yields better benefit, but the sample size is small.